1-Bromododecane | CAS:143-15-7

We serve 1-Bromododecane CAS:143-15-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
1-Bromododecane

Chemical Name:1-Bromododecane
CAS.NO:143-15-7
Synonyms:Lauryl Bromide
bromododecane
1-dodecyl bromide
1-bromo dodecane
Molecular Formula:C12H25Br
Molecular Weight:249.23100
 
Physical and Chemical Properties:
Density:1.040;
Melting point:-11oC;
Boiling point:134-135oC;
Flash point:230oF;
Index of Refraction:1.458;
 
Specification:
Appearance:Colorless to pale yellow liquid
Purity(GC):≥99.0%
Moisture:≤0.1%
pH:6.0-7.0
Non-volatile matter:≤10ppm
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Synthesis:Prepared by reacting 1-Dodecanol with hydrobromic acid or sodium bromide
Application:As an intermediate in organic synthesis



Contact us for information like 1-Bromododecane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-bromo dodecane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-dodecyl bromide Use and application,1-Bromododecane technical grade,usp/ep/jp grade.


Related News: What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.N-[[dimethoxy(methyl)silyl]oxymethyl]aniline manufacturer What is the difference? Raw material refers to chemical compounds that are used as a base to make an API.methyl 2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetate supplier At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.2,2-Difluoro-1,3-benzodioxole-4-carboxylic acid vendor At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.